Summary
Recent studies have shown that decreased intracellular NAD+ levels can lead to age-related diseases, while treatments that increase intracellular NAD+ levels can prevent these diseases in animal models.
Nicotinamide mononucleotide (NMN) administration has been shown to alleviate age-related functional impairments. However, the safety of NMN in humans remains unclear. Therefore, we conducted a clinical trial to investigate the safety of a single NMN dose in 10 healthy men. This study employed a single-arm, non-randomized interventional design, with single oral doses of 100, 250, and 500 mg NMN. Clinical manifestations and parameters, as well as the pharmacokinetics of NMN metabolites, were observed within 5 hours after each intervention. Ophthalmological examinations and sleep quality assessments were also performed before and after the intervention.
The results showed that a single oral dose of NMN did not cause any significant clinical symptoms, nor did it cause changes in heart rate, blood pressure, blood oxygen saturation, or body temperature. Laboratory analysis showed no significant changes, except for an increase in serum bilirubin levels. Serum creatinine, chloride, and blood glucose levels remained within the normal range and were not related to the NMN dose. Ophthalmological examination and sleep quality scores showed no difference before and after the intervention. After NMN administration, plasma concentrations of N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide showed a dose-dependent and significant increase. A single oral dose of NMN was safe and effective in healthy men, without causing any significant adverse reactions. Therefore, oral NMN is feasible, suggesting it may be a potential therapeutic strategy for alleviating age-related diseases in humans.
Source: Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men, Endocrine Journal
